Triple
T22690134
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | A10BJ05 |
E561028
|
entity |
| Predicate | relatedDrug |
P68633
|
FINISHED |
| Object |
lixisenatide
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes.
|
E1549310
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: lixisenatide | Statement: [A10BJ05, relatedDrug, lixisenatide]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: lixisenatide Context triple: [A10BJ05, relatedDrug, lixisenatide]
-
A.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
B.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
-
C.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
E.
Wegovy
Wegovy is a prescription weight-loss medication (semaglutide) developed by Novo Nordisk, used to help adults with obesity or overweight manage their weight alongside diet and exercise.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: lixisenatide Triple: [A10BJ05, relatedDrug, lixisenatide]
Generated description
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: lixisenatide Target entity description: Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes.
-
A.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
B.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
-
C.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
E.
Wegovy
Wegovy is a prescription weight-loss medication (semaglutide) developed by Novo Nordisk, used to help adults with obesity or overweight manage their weight alongside diet and exercise.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a0b73fa5a648190b90ba303d1fe2397 |
completed | May 18, 2026, 8:18 p.m. |
| NEDg | Description generation | batch_6a0b7755eb048190ba1657a9a09bc24b |
completed | May 18, 2026, 8:32 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0b780c0a4c8190b51b50c1e0e1a114 |
completed | May 18, 2026, 8:35 p.m. |
Created at: April 17, 2026, 3:13 p.m.